Plain-English translation of NCT07570173 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called to see if it works better than or as well as an existing treatment called for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back or stopped responding to previous treatment. The trial has two parts: first, researchers will figure out the best dose of the medication, and then they will compare it head-to-head with the existing treatment to see which works better and is safer.
People with relapsed or refractory B-cell acute lymphoblastic leukemia have limited treatment options and need new therapies that might work better. This trial is testing whether this new medication could offer patients a more effective way to fight their cancer.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an injection once a week for up to 13 cycles (about 12 to 14 months total). The first two cycles last 28 days each, and the remaining cycles last 42 days. You will have regular clinic visits for blood tests, scans, and check-ups to monitor how well the treatment is working and manage any side effects. At the end of the first part of the trial, you will have the option to continue with the same dose or switch to a different dose based on how you are responding.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
Denmark
Israel